TAFAZZIN and Barth syndrome: Although the effect in islets is milder, we believe it mimics the clinical scenario observed in human carriers of Taz loss-of-function mutations, who show mild or no endocrine symptoms, while still recapitulating the cardiac dysfunction characteristic of BTHS.